- About Us
- Clinical Trials
- News & Publications
- Business Development
July 3, 2019
Source: Methods Enzymol. 2020;632:55-65. doi: 10.1016/bs.mie.2019.05.045. Epub 2019 Jul 3.
Authors: A.M. Chalupova, S. Vosahlikova, D. Rozkova, K. Sochorova, L. Palova-Jelinkova, J. Bartunkova, R. Spisek, J. Fucikova.
Dendritic cells have been widely investigated in cancer immunotherapy clinical trials for the last two decades mainly due to their robust ability to elicit an adaptive anticancer immune response of the cellular and humoral types. Immature DCs can be easily loaded with desired antigens. However, to become efficient antigen-presenting cells, DCs must first undergo a process of maturation. Protocols for the generation of DCs for use in cancer immunotherapy, including the generation of a large number of immature DCs for antigen pulsing and the selection of a well-defined immunostimulatory agent to achieve complete and reproducible maturation, which is a crucial step for further stimulation of T cell activation, must carefully consider the characteristics of DC physiology. In this report, we provided a detailed protocol for DC generation, pulsation and activation with the subsequent induction of T cell-specific immune responses.